Oral semaglutide (N = 28) Oral semaglutide + omeprazole (N = 26) Semaglutide AUC0–24h,semaglutide,Day10, estimated means (95%CI), nmol⋅h/L 290 (235, 358) 328 (265, 407) Cmax,semaglutide,Day10, estimated means (95%CI), nmol/L 15.2 (12.3, 18.8) 17.6 (14.1, 21.8) tmax,semaglutide,Day10, median (min, max), h 1.0 (0.2, 4.0) 1.0 (1.0, 6.0) t½, geometric mean (CV), h 150 (9.6) 156 (9.5) SNAC AUC0–24h,SNAC,Day10, estimated means (95%CI), ng⋅h/mL 1129 (1029, 1238) 1284 (1169, 1410) Cmax,SNAC,Day10, estimated means (95%CI), ng/mL 1028 (804, 1314) 986 (768, 1267) tmax,SNAC,Day10, median (min, max), h 0.7 (0.2, 4.0) 0.6 (0.1, 10.0) t½, geometric mean (CV), h –– AUC, area under the plasma concentration–time curve; CI, confidence intervals; CV, coefficient of variation; h, hour; SNAC, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate; tmax, time to maximum; t1/2, half life. Figure 4. Pharmacokinetics of SNAC after the 10th dosing. (a). Mean plasma concentration–time profile of SNAC. (b) Comparison of AUC0–24h and Cmax for SNAC between the oral semaglutide and oral semaglutide plus omeprazole groups.